Trial · Observational
Status unknownPhase not statedRegistry dataShort name GLP-1REWIN
This trial does not test a peptide that PepBank tracks.
Italy
1 trial
Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.
Glucagon-like peptide-1 receptor agonists (GLP-1RA) are powerful second-line agents for the treatment of type 2 diabetes. GLP-1RA have bene marketed in 2010 in Italy and years of experience have accumulated for the treatment with this class of drugs. Cardiovascular outcome trials have shown that type 2 diabetic patients with established cardiovascular disease treated with GLP-1RA have a lower risk of future cardiovascular events. In this real world study, we wish to evaluate retrospectively the effectiveness and persistence on treatment of GLP-1RA therapy in patients with type 2 diabetes from 2010 to 2018. Effectiveness endpoints will be glycemic (fasting plasma glucose and HbA1c) and extra-glycemic (body weight and blood pressure). Data from diabetes outpatient clinics in North East Italy will be automatically extracted from electronic chart records and collected into a unique database. Different groups of GLP-1RA therapies will be compared: * Long-acting (e.g. dulaglutide and exenatide once weekly) versus short acting (exenatide, liraglutide and lixisenatide) * Fixed versus flexible combinations of GLP-1RA and basal insulin. * GLP-1RA with similarities to human GLP-1 (e.g. liraglutide) versus exendin-based GLP-1RA (e.g. exenatide).
Other
Long-acting GLP-1RA
Patients who have been treated with weekly GLP-1RA (exenatide once weekly or dulaglutide)
Other
Short-acting GLP-1RA
Patients who have been treated with daily GLP-1RA (exenatide bid or liraglutide or lixisenatide)
Other
Human GLP-1 based GLP-1RA
Patients who have been treated with GLP-1RA based on human GLP-1 (dulaglutide or liraglutide)
Other
Exendin-based GLP-1RA
Patients who have been treated with weekly GLP-1RA (exenatide or lixisenatide)
Other
Fixed ratio combination of BI/GLP-1RA
Patients who have been treated with a fixed ratio combination of GLP-1RA and basal insulin (BI), such as IdegLira (insulin degludec / liraglutide) or IglarLixi (insulin glargine / lixisenatide)
Other
Flexible combination of BI/GLP-1RA
Patients who have been treated with any GLP-1RA in combination with any basal insulin (BI)
Outcomes the sponsor listed as primary.
HbA1c
Time frame · 3-12 months
Change in HbA1c from baseline to end of follow-up
Weight
Time frame · 3-12 months
Change in body weight from baseline to end of follow-up
Blood pressure
Time frame · 3-12 months
Change in systolic blood pressure from baseline to end of follow-up
Persistence
Time frame · 3-12 months
Percentage of patients who persist on treatment at the end of follow-up
Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.
No results are posted for this trial.
A trial that is still running, or that stopped early, may post results later.
Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works
Studies that cite this trial.
3 studies on this page
Indexing hint: Meta-analysis (pooled) · 2018
Bethel et al. 2018The lancet. Diabetes & endocrinologycited by 476
PMID 29221659DOI 10.1016/s2213-8587(17)30412-6PUB-29221659
Indexing hint: Meta-analysis (pooled) · 2017
Singh et al. 2017Diabetes, obesity & metabolismcited by 84
PMID 27717130PMC5299485DOI 10.1111/dom.12805PUB-27717130
Indexing hint: Meta-analysis (pooled) · 2017
Abd El Aziz et al. 2017Diabetes, obesity & metabolismcited by 116
PMID 27717195DOI 10.1111/dom.12804PUB-27717195
References listed at the registry that are not in PepBank. They link to PubMed.
Who could join, as posted.
PepBank is a research reference. Talk to a doctor before you use any peptide.
In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated